These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29888865)

  • 1. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
    Canis K; Anzengruber J; Garenaux E; Feichtinger M; Benamara K; Scheiflinger F; Savoy LA; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
    O'Sullivan JM; Jenkins PV; Rawley O; Gegenbauer K; Chion A; Lavin M; Byrne B; O'Kennedy R; Preston RJ; Brophy TM; O'Donnell JS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):855-63. PubMed ID: 27013611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
    Esmon PC; Kuo HS; Fournel MA
    Blood; 1990 Oct; 76(8):1593-600. PubMed ID: 1698481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.
    Kannicht C; Ramström M; Kohla G; Tiemeyer M; Casademunt E; Walter O; Sandberg H
    Thromb Res; 2013 Jan; 131(1):78-88. PubMed ID: 23058466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A.
    Diego VP; Luu BW; Hofmann M; Dinh LV; Almeida M; Powell JS; Rajalingam R; Peralta JM; Kumar S; Curran JE; Sauna ZE; Kellerman R; Park Y; Key NS; Escobar MA; Huynh H; Verhagen AM; Williams-Blangero S; Lehmann PV; Maraskovsky E; Blangero J; Howard TE
    J Thromb Haemost; 2020 Jan; 18(1):201-216. PubMed ID: 31556206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.
    Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M
    Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
    Mannully ST; L N R; Pulicherla KK
    Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular Stress Induced by Plasma-Derived Factor VIII Products.
    Brodde M; Müller A; Kehrel B
    Transfus Med Hemother; 2014 Apr; 41(2):140-4. PubMed ID: 24847190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
    Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
    Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.
    Kosloski MP; Miclea RD; Balu-Iyer SV
    AAPS J; 2009 Sep; 11(3):424-31. PubMed ID: 19499345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Recombinant Factor VIII in Human Cell Lines.
    Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2018; 1674():63-74. PubMed ID: 28921428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.